<DOC>
	<DOCNO>NCT02939274</DOCNO>
	<brief_summary>The purpose Phase II study evaluate efficacy safety Continuous Low- Irradiance Photodynamic Therapy ( CLIPT ) use Verteporfin treatment cutaneous metastasis breast cancer curative significantly palliative therapy exists , include chest wall therapy .</brief_summary>
	<brief_title>An Open Label , Phase II Trial Continuous Low-Irradiance Photodynamic Therapy ( CLIPT ) Using Verteporfin ( VisudyneÂ® ) Treatment Cutaneous Metastases Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Histologically cytologically confirm Stage IIIb IV breast cancer cutaneous metastasis . Participants receive medication substance know cause photosensitivity ( e.g . tetracycline , sulfonamide , phenothiazine , sulfonylurea hypoglycemic agent , thiazide diuretic , griseofulvin , fluoroquinolones , St. Johns ' wort , amiodarone ) ineligible . Participants receive prior systemic therapy ( chemotherapy target therapy ) within 7 day Study Day 1 recover clinically significant adverse event due agent administer 7 day earlier . ( continuation regimen HER2 antibody target therapy agent , hormonal therapy treatment bisphosphonates denosumab permit ) Participants receive investigational agent propose treatment cycle .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>